Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to -$15.6 million.

  • Apellis Pharmaceuticals' Change in Account Payables fell 125043.18% to -$15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 9211.28%. This contributed to the annual value of $1.1 million for FY2024, which is 54058.82% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Change in Account Payables stood at -$15.6 million, which was down 125043.18% from -$1.0 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Change in Account Payables ranged from a high of $23.1 million in Q4 2022 and a low of -$15.6 million during Q3 2025
  • For the 5-year period, Apellis Pharmaceuticals' Change in Account Payables averaged around $1.6 million, with its median value being -$1.0 million (2025).
  • Over the last 5 years, Apellis Pharmaceuticals' Change in Account Payables had its largest YoY gain of 92540.05% in 2022, and its largest YoY loss of 856746.99% in 2022.
  • Apellis Pharmaceuticals' Change in Account Payables (Quarter) stood at $13.7 million in 2021, then soared by 68.8% to $23.1 million in 2022, then fell by 15.16% to $19.6 million in 2023, then tumbled by 92.42% to $1.5 million in 2024, then plummeted by 1150.94% to -$15.6 million in 2025.
  • Its last three reported values are -$15.6 million in Q3 2025, -$1.0 million for Q2 2025, and $16.7 million during Q1 2025.